Impact of intracoronary administration of nitroprusside vs. nitroglycerine before balloon dilatation on slow reflow during percutaneous coronary intervention in patients with acute ST elevation myocardial infarction




Background


Retrospective data have shown that selective intracoronary administration of nitroprusside prior to percutaneous coronary intervention (PCI) is safe, prevents no or slow reflows and improves reperfusion of the infarcted myocardium for acute myocardial infarction (AMI). There is paucity of prospective data regarding the usefulness of this therapy.




Methods


We randomly assigned 87 consecutive patients with AMI to perform PCI with nitroprusside (44 patients) or with nitroglycerine (43 patients). Nitroglycerine (200 μg) or nitroprusside (120 μg) was selectively administered through the drug delivery catheter into the distal coronary artery to reach the target lesion before balloon dilatation. Clinical and angiographic data, as well as in-hospital outcomes, of the nitroprusside group were compared with those of the nitroglycerine group.

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Coronary stenting with MGuard: extended follow-up of first human trial
  2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
  3. Treatment of STEMI with neither PCI nor thrombolysis
  4. Definite stent thrombosis: a 2-center New Zealand registry

Stay updated, free articles. Join our Telegram channel
Tags:
Nov 16, 2017 | Posted by in CARDIOLOGY | Comments Off on Impact of intracoronary administration of nitroprusside vs. nitroglycerine before balloon dilatation on slow reflow during percutaneous coronary intervention in patients with acute ST elevation myocardial infarction

Full access? Get Clinical Tree
Get Clinical Tree app for offline access